Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:DFFNNASDAQ:EVOKNASDAQ:ITRM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.19+1.7%$1.22$0.59▼$11.12$84.41M0.221.51 million shs1.63 million shsDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsEVOKEvoke Pharma$0.44-2.2%$0.60$0.42▼$2.40$3.70M0.2253,776 shs15,641 shsITRMIterum Therapeutics$1.57+1.3%$1.51$0.62▼$2.50$25.46M2.36145,315 shs50,845 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+1.71%-3.25%+0.85%-3.25%-86.61%DFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-22.60%EVOKEvoke Pharma-2.57%-8.94%-27.90%-33.44%-76.93%ITRMIterum Therapeutics+1.29%+9.79%+0.64%-8.72%+57.00%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics1.7415 of 5 stars3.11.00.00.02.61.71.3DFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.2106 of 5 stars3.53.00.00.00.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,769.75% UpsideDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00282.17% UpsideCurrent Analyst RatingsLatest DFFN, ACRS, ITRM, and EVOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.70N/AN/A$2.22 per share0.54DFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AEVOKEvoke Pharma$5.18M0.71N/AN/A($0.77) per share-0.57ITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)DFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AEVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)Latest DFFN, ACRS, ITRM, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million 2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16DFFNDiffusion PharmaceuticalsN/A10.7110.71EVOKEvoke PharmaN/A2.252.09ITRMIterum Therapeutics3.631.891.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%DFFNDiffusion Pharmaceuticals9.95%EVOKEvoke PharmaN/AITRMIterum Therapeutics9.21%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%DFFNDiffusion Pharmaceuticals1.80%EVOKEvoke Pharma11.78%ITRMIterum Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableDFFN, ACRS, ITRM, and EVOK HeadlinesSourceHeadlineIterum Therapeutics (NASDAQ:ITRM) vs. RedHill Biopharma (NASDAQ:RDHL) Head to Head Contrastamericanbankingnews.com - April 25 at 1:39 AMIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 10:27 AMIterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 6:45 PMQ4 2023 Iterum Therapeutics PLC Earnings Callfinance.yahoo.com - March 29 at 2:40 AMIterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 28 at 11:34 AMIterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 7:00 AMIterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024globenewswire.com - March 21 at 4:30 PMIterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chatglobenewswire.com - March 15 at 8:00 AMEQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovationsmarkets.businessinsider.com - March 12 at 10:42 AMIterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Upzacks.com - March 7 at 9:00 AMIterum Therapeutics Provides Business Updatefinance.yahoo.com - March 6 at 7:38 PMIterum Therapeutics PLC (ITRM)investing.com - February 28 at 7:36 AMIterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63msn.com - February 24 at 2:19 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLCfinance.yahoo.com - February 1 at 4:09 PMIterum Shareholders Reject Board’s Share Issuance Proposalmsn.com - February 1 at 12:05 AMIterum Therapeutics Announces Triumph in Phase 3 uUTI Trialmsn.com - January 31 at 7:49 AMWhy Iterum Therapeutics Stock Is Trending Todaymsn.com - January 30 at 4:48 PMIterum meets main goal in late trial for uUTI treatment with oral sulopenemmsn.com - January 30 at 4:48 PMIterum Therapeutics's Late-stage REASSURE Trial Successfully Met Primary Endpointmarkets.businessinsider.com - January 30 at 4:48 PMIterum Therapeutics Says UTI Drug Trial Met Primary Endpointmarketwatch.com - January 30 at 9:45 AMIterum Therapeutics Shares Surge on Positive UTI Drug Trial Resultsmarketwatch.com - January 30 at 9:45 AMIterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infectionsfinance.yahoo.com - January 30 at 9:45 AMThe Potential Rise in the Price of Iterum Therapeutics Plc (ITRM) following insiders activityknoxdaily.com - January 1 at 8:29 AMInsiders Buying Iterum Therapeutics And 3 Other Stocks Under $3msn.com - December 28 at 1:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Diffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.